Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Signe Risum; Ulrich Knigge; Seppo W Langer

doi:10.1002/ccr3.1262

Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Signe Risum, Ulrich Knigge, Seppo W Langer

Abstract

Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

Original language	English
Journal	AACE clinical case reports
Volume	5
Issue number	12
Pages (from-to)	2085-2087
Number of pages	3
ISSN	2376-0605
DOIs	https://doi.org/10.1002/ccr3.1262
Publication status	Published - Dec 2017

Keywords

Journal Article

Access to Document

10.1002/ccr3.1262

Cite this

@article{202067719a5d4e8f87ee0bb4b104e88c,

title = "Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine",

abstract = "Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.",

keywords = "Journal Article",

author = "Signe Risum and Ulrich Knigge and Langer, {Seppo W}",

year = "2017",

month = dec,

doi = "10.1002/ccr3.1262",

language = "English",

volume = "5",

pages = "2085--2087",

journal = "Clinical Case Reports",

issn = "2050-0904",

publisher = "JohnWiley & Sons Ltd",

number = "12",

}

TY - JOUR

T1 - Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

AU - Risum, Signe

AU - Knigge, Ulrich

AU - Langer, Seppo W

PY - 2017/12

Y1 - 2017/12

N2 - Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

AB - Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

KW - Journal Article

U2 - 10.1002/ccr3.1262

DO - 10.1002/ccr3.1262

M3 - Journal article

C2 - 29225862

VL - 5

SP - 2085

EP - 2087

JO - Clinical Case Reports

JF - Clinical Case Reports

SN - 2050-0904

IS - 12

ER -

Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Abstract

Keywords

Access to Document

Fingerprint

Cite this